Why is Insulet (PODD) stock down today?
Insulet stock is having its worst day in 17 years after the company cut its full-year revenue growth outlook despite beating Q2 earnings and revenue estimates.
What happened
Insulet Corporation fell 20.12% to $133.26 on August 5, 2026 — its worst single-day decline in 17 years, according to Barron's — after the company lowered its full-year revenue growth outlook following its Q2 2026 earnings report. The paradox driving the selloff is that Insulet actually beat estimates: Q2 earnings per share came in at $1.66 versus the $1.45 consensus estimate, and revenue also exceeded expectations. When a company beats near-term results but cuts forward guidance, investors reprice the stock based on the dimmer outlook, not the backward-looking beat — and that mechanism is driving the steep drop today.
The guidance cut triggered swift analyst target reductions. Piper Sandler slashed its price target to $160 from $210, and Citigroup cut its target to $150 from $172. Multiple downward revisions arriving simultaneously reinforce selling pressure as portfolio managers who had held the stock based on higher growth assumptions reassess their positions. The GuruFocus earnings call recap specifically noted that strong revenue growth was 'offset by' Type 2 diabetes-related headwinds, pointing to pressure in that segment as a key factor behind the reduced outlook.
The broader market provided little cushion. The S&P 500 (^GSPC) was down 0.17% and the Nasdaq 100 (QQQ) was off 0.90% on the same session, meaning Insulet's 20% drop was almost entirely company-specific and not a product of a broad market selloff. Insulet was flagged as one of the top losers in the S&P 500 and a stock with unusually high trading volume during Wednesday's session.
As of the close of trading on August 5, 2026, Insulet's market cap stood at approximately $9.23 billion, down sharply from the prior session's implied valuation. The stock traded in a wide range of $126.50 to $138.41 during the day, reflecting significant uncertainty as the market digested the revised outlook. Upcoming jobs data — including Non-Farm Payrolls and the Unemployment Rate due August 7 — may influence the broader market backdrop in coming sessions, though those are macro events unrelated to Insulet's company-specific story.
The catalysts, cited
Insulet lowers full-year revenue growth outlook despite Q2 earnings and revenue beat — worst S&P 500 stock on the day
Yahoo
This Medtech Beat Earnings, but the Stock Is Having Its Worst Day in 17 Years
Barrons.com
Piper Sandler cuts Insulet price target to $160 from $210
MT Newswires
Citigroup cuts Insulet price target to $150 from $172
MT Newswires
Insulet Corp Q2 2026 Earnings Call Highlights: Strong Revenue Growth Offset by Type 2 headwinds
GuruFocus.com
What to watch next
- Average Hourly Earnings, Non-Farm Payrolls, and Unemployment Rate (macro data)
Moving with it
Why is MDLN moving?
Why is ^GSPC moving?People also ask
Why is Insulet stock down so much today?
Insulet cut its full-year revenue growth outlook after reporting Q2 2026 results, even though earnings per share ($1.66) and revenue both beat analyst estimates. When a company lowers forward guidance, the market reprices based on the weaker outlook, which drove the stock down more than 20% — its worst single-day drop in 17 years.
Did Insulet beat or miss earnings?
Insulet beat Q2 2026 earnings estimates, posting EPS of $1.66 against a $1.45 consensus estimate, and revenue also came in above expectations. The selloff was driven by the company's lowered full-year revenue growth guidance, not the quarterly results themselves.
Why did analysts cut their price targets on Insulet?
Following the earnings report and guidance cut, Piper Sandler reduced its price target to $160 from $210, and Citigroup cut its target to $150 from $172. Analyst target reductions typically reflect a reassessment of the company's near-term growth prospects based on the new, lower guidance.
Is the whole market down today, or is this just Insulet?
The broader market was only modestly lower — the S&P 500 fell about 0.17% and the Nasdaq 100 dropped about 0.90% on the same day. Insulet's 20% decline was almost entirely company-specific, driven by its lowered revenue growth outlook, not a broad market selloff.